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LETTERS TO THE EDITOR
Regarding “Optimal therapy for advanced chronic
venous insufficiency”
The article by Tawes et al (J Vasc Surg 2003;37:545-51)
concerning subfascial endoscopic perforating vein surgery (SEPS)
raised a number of questions. It is difficult to understand how the
authors could conclude that “efficacy, safety, and durability of this
operative protocol proved beneficial in our clinical experience with
832 patients during 9 years of follow-up,” when mean follow-up
was only 31⁄2 years. How many patients completed 9 years of
follow-up in this study?
What percentage of clinical improvement was due to SEPS
versus saphenous vein stripping, which was performed in more
than half of the patients? Concerning duplex scanning to detect
venous insufficiency, should this be done with the patient sitting?
Why were veins larger than 2.5 mm in diameter arbitrarily judged
incompetent? It is not clear why it was stated that “duplex may be
omitted by experienced surgeons.” I am also concerned about the
conclusion that “SEPS had significantly reduced [arteriovenous
pressure],” when almost half the patients did not undergo the
examination. Finally, have the authors recommended elastic stock-
ings? If so, what role did this have in mean time to ulcer healing?
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As cited in our manuscript, controversy has existed for decades
about the relative contribution of reflux in the deep, superficial,
and perforator venous systems to chronic venous insufficiency
(CVI). If it is accepted that major factors in the cause of CVI are
pathologic hydrostatic (superficial) and hydrodynamic (perforator)
forces, it does not require a quantum leap of faith to direct the
operation to correct these sources of reflux and evaluate the
outcome over a sufficient period of time. This was the bias and
objective of our study.
Noninvasive technology (duplex scanning) is available that
enables diagnosis and specifically targets these sources, and mini-
mally invasive, video-assisted endoscopic surgery provides a reli-
able means for correction of perforator vessel reflux.
Until level I evidence is available, we offer our operative
protocol, ie, subfascial endoscopic perforating vein surgery (SEPS)
as an effective interim measure. Most ulcers healed in 7 weeks
(mean). Almost 9 of 10 patients benefited over time; 416 patients
were followed up for more than 31⁄2 years, 60 patients for more
than 5 years, and 22 patients for more than 9 years. Our approach
was associated with a 3% complication rate (30 days). Inasmuch as
most of the poor results (nonhealing or recurrence of CVI) oc-
curred early, we consider SEPS not only efficacious, but also
durable. Redo SEPS further improves long-term results (see Re-
sults).
With regard to duplex scanning, no cases had fewer than three
positive reflux points; therefore “arbitrary” designations did not
influence inclusion criteria or outcome (see Methods).
All patients were examined with their legs dependent (sit-
ting or standing). All 832 patients underwent diagnostic duplex
scanning. Additional preoperative mapping duplex scanning
may be omitted by experienced surgeons with a sound knowl-
edge of perforator topographic and operative anatomy, inas-
much as there was a disparity between perforator vessels mapped
(mean, 4) versus those identified at surgery (mean, 7). How-
ever, mapping is a useful “targeting” method for the surgeon
early in the learning curve.
The subset “Dusseldorf experience” demonstrated a signifi-
cant decrease in AVP after SEPS, with significant improvement in
VRT to normal (see Tables III and IV). This cohort was prospec-
tively randomized, and provided objective statistical data to sup-
port our operative protocol. All cohort patients underwent greater
saphenous vein ligation and stripping; therefore we did not intro-
duce a variable for analysis (see data).
Elastic stockings are recommended, but their role was not
evaluated in this study insofar as compliance and time to ulcer
healing and disease recurrence.
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Regarding “The safety, efficacy, and
pharmacoeconomics of low-dose alteplase compared
with urokinase for catheter-directed thrombolysis of
arterial and venous occlusions”
We read with interest the article by Sugimoto et al (J Vasc Surg
2003;37:512-7) reporting that continuous overnight infusion of
low-dose tissue plasminogen activator (t-PA) combined with sub-
therapeutic dosage of heparin is equally efficacious and safe com-
pared with urokinase for treatment of arterial occlusive disease and
deep vein thrombosis. We would like to point out that both of
these diseases and the effect of anticoagulant therapy demonstrate
significant temporal variation, which should not be overlooked in
planning studies and interpreting their results. Like many other
acute cardiovascular events, acute arterial occlusion of the limbs1
and pulmonary embolism2 exhibit a circadian pattern of occur-
rence, with higher incidence in the morning. This morning excess
appears to be related to increased platelet aggregability and re-
duced endogenous fibrinolysis during this time. Opposite circa-
dian patterns, characterized by lower levels of tissue-type plas-
minogen-activator and higher values of t-PA and higher values of
t-PA inhibitor-1, with variations up to 250%, have been reported.3
On the other hand, circadian changes in anticoagulant effect of
heparin, even when infused intravenously at a constant rate, have
been reported.4 Activated partial thromboplastin time (aPTT),
thrombin time (TT), and coagulation factor Xa inhibition assay
achieve maximal values at night, with differences between night
and morning values of almost 50% for aPTT, 60% for TT, and 40%
for factor Xa inhibition assay. As a consequence, a constant dose
could have poor effects in the morning and enhance the risk for
bleeding at night. A morning increase in resistance to thrombolysis
performed to treat acute myocardial infarction has also been re-
ported with both intracoronary urokinase5 and intravenous t-PA.6
In light of these data, it appears that, in comparing the efficacy and
safety of various thrombolytic therapies, an imbalance in onset time
of the event or time of administration of anticoagulant or fibrino-
lytic agent could justify possible differences in clinical outcome.
Tailoring thrombolytic therapy and adjusting dosages according to
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